ASCO GU 2023

Bladder preservation strategies - promising data but no change in SoC yet?!

New updates on immunocheckpoint inhibitors and ADCs - which therapy for which patient?

Robust DFS benefit, but lack of OS data leaves open questions

Re-shaping bladder cancer treatment

No change in SoC, but new genomic predictors for EV outcome

Atezo monotherapy for mUC

Benefit of neoadjuvant pembro for CE and CI patients

Update / German Real World Data M1 BC

No final OS difference - but subgroups may benefit from Atezolizumab

PD-1 as combo in 1st line

Urothelial cancer highlights from ASCO GU23

Final overall survival

IMvigor130: final OS

Final OS data show no significant benefit for chemo plus ICI

Pembro for HR NMIBC

NMIBC highlights from ASCO GU23

Checkpoint inhibition in adjuvant therapy

New data for pembro in HR NIMBC

Exciting survival data for adjuvant NIVO

Impressive DFS with adjuvant Nivo in biomarker-positive patients

Pembrolizumab in HR NIMBC

Urothelial cancer - hidden gems of the poster session

3 yrs outcome of Nivo for adjuvant therapy

The bladder cancer highlights of ASCO GU

Επισημάνσεις για τον καρκίνο του ουροθηλίου από την ASCO GU23

BCG yanıtsız yüksek riskli KİOMK tedavisinde Pembrolizumab

PARPi are effective in PCa - which subgroups benefits most?

Refinando el tratamiento del cancere vejiga

Los aspectos más destacados del ASCO GU 2023 en cáncer de vejiga

The bladder cancer highlights of ASCO GU

BRCA mutations in mCRPC - the importance of biomarkers in PCa! Why we need better testing and better understanding of therapy combinations!

Benefits and risks of precision medicine with PARPi

Triplet combination - all-comer therapy or high risk high volume only? How do we identify the patients who benefit?

ARASENS: triple independent of volume and risk

Normal baseline testosterone level is a strong predictor of post-ADT recovery

Monotherapy is not any longer standard of care

Formula 509: Racing to a better straegy for radiotherapy

Intensification of salvage therapy in high risk settings

ARASENS - post-hoc subgroup analysis

Benefit in all groups

MMAI - a superior prognostic marker for high risk patients

mHSPC - new standard and more insights

Surgery vs. Radiation for N1 PCa: who wins?

PARP and testing

New ways to target androgen receptor signaling

Controversy in ADT roundtable

Doublet or all-in: the solution for all patients?

Rucaparib: treatment option for biomarker-selected patients

TALA ENZO with improved PFS in mCRPC

PARPi combo approval for all-comers - balancing benefit of treamtent vs. side effects is crucial

Rucaparib - the new player?

PARPi combo: all-comer treatment for mCRPC

Propel - final OS

PARPi combination in mCRPC

Encouraging results for Talazoparib

PARPi & ARPi with wonderful data

TALA in 1st line for all patients with mCRPC

Tiebreaker for previous trials

PARPi are effective in PCa - which subgroup benefits most?

Rucaparib - ready for clinical practice in BRCAmut patients

PARPi study with different design

MMAI- Yüksek riskli prostat kanserinde üstün bir prognostik belirteç

PARPi & ARPi με υπέροχα δεδομένα

Lokalize prostat kanserinde cerrahi ile SBRT karşılaştıran faz-3 randomize kontrollü çalışma

RP sonrası kurtarma RT ile GnRH Analog ABİ APA kombinasyonu, kurtarma RT ve GnRH analog tedavisinden daha iyi PFS sağlar mı?

Nya vägar att blockera androgenreceptor signalering

edavi öncesi normal testosteron seviyesi ADT sonrası testosteron geri dönüşü için güçlü bir prediktördür

miR371'in orşiektomi sonrası tedavi seçimini yönlendirmekteki yüksek doğruluğu

TALA ENZA kombinasyonu ile mKDPK olan hastalarda daha iyi progresyonsuz sağkalım

Ny PARP hämmar studie med anna design

Updated data of CheckMate 9ER - impact on real-world therapy

Theranostics in RCC - usefull tools for ccRCC?!

Novel updates on cabozantinib in advance RCC

New therapy choices for renal cell cancer patients

Longer FU confirms significant benefit of Nivo-Cabo, Cabo effective post IO first line

Reassuring update of CM9ER with longer follow up

Outcomes of patients with brain metastases treated with first-line therapies

Hypothesis-generating differences in risks groups

Zircon-PET in RCC

First prospective data on 2nd line therapy after IO combination in mRCC

High accuracy of miR371 to guide treatment selection after orchiectomy

Refining prediction of stage I seminoma

Mejorando la estimacion pronostica en Seminoma Estadio I